A1LN34 Stock Overview
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Alnylam Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.80 |
| 52 Week High | US$51.52 |
| 52 Week Low | US$36.23 |
| Beta | 0.40 |
| 1 Month Change | 4.33% |
| 3 Month Change | -16.74% |
| 1 Year Change | n/a |
| 3 Year Change | -1.77% |
| 5 Year Change | n/a |
| Change since IPO | -7.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| A1LN34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | -1.9% | 1.5% | 0.7% |
| 1Y | n/a | -4.8% | 14.9% |
Return vs Industry: Insufficient data to determine how A1LN34 performed against the BR Biotechs industry.
Return vs Market: Insufficient data to determine how A1LN34 performed against the BR Market.
Price Volatility
| A1LN34 volatility | |
|---|---|
| A1LN34 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 8.7% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: A1LN34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A1LN34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 2,100 | Yvonne Greenstreet | www.alnylam.com |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.
Alnylam Pharmaceuticals, Inc. Fundamentals Summary
| A1LN34 fundamental statistics | |
|---|---|
| Market cap | R$95.08b |
| Earnings (TTM) | -R$2.27b |
| Revenue (TTM) | R$9.41b |
9.9x
P/S Ratio-41.3x
P/E RatioIs A1LN34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A1LN34 income statement (TTM) | |
|---|---|
| Revenue | US$1.83b |
| Cost of Revenue | US$310.41m |
| Gross Profit | US$1.52b |
| Other Expenses | US$1.96b |
| Earnings | -US$440.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -3.48 |
| Gross Margin | 83.02% |
| Net Profit Margin | -24.08% |
| Debt/Equity Ratio | -1,086.8% |
How did A1LN34 perform over the long term?
See historical performance and comparison